The demonstration that immune and epithelial cells can discriminate between different microbial species has extended our understanding of the actions of probiotics beyond simple barrier and antimicrobial concepts. Several probiotic mechanisms of action, relative to inflammatory bowel disease, have been elucidated: (1) competitive exclusion, whereby probiotics compete with microbial pathogens for a limited number of receptors present on the surface epithelium; (2) immunomodulation and/or stimulation of an immune response of gut-associated lymphoid and epithelial cells; (3) antimicrobial activity and suppression of pathogen growth; (4) enhancement of barrier function; and (5) induction of T cell apoptosis in the mucosal immune compartment. The unraveling of these mechanisms of action has led to new support for the use of probiotics in the management of clinical inflammatory bowel disease. Though level 1 evidence now supports the therapeutic use of probiotics in the treatment of postoperative pouchitis, only levels 2 and 3 evidence is currently available in support of the use of probiotics in the treatment of ulcerative colitis and Crohn's disease. Nevertheless, one significant and consistent finding has emerged during the course of research in the past year: not all probiotic bacteria have similar therapeutic effects. Rigorously designed, controlled clinical trials are vital to investigate the unresolved issues related to efficacy, dose, duration of use, single or multi-strain formulation, and the concomitant use of prebiotics, synbiotics, or antibiotics.
T he mammalian intestinal tract is home to a complex and diverse society of pathogenic and nonpathogenic bacteria. Historically, microbial research has focused on the mechanisms by which pathogenic bacteria exert their detrimental effects. However, more recent research has provided a glimpse into the health-related roles played by indigenous, nonpathogenic microorganisms (probiotics). Probiotics, prebiotics, and synbiotics are moving into the mainstream of medical therapy. This new acceptance has been facilitated by our increased understanding of the mechanisms of action by which these agents exert their beneficial effects, by the development of molecular methods for analyzing and identifying complex bacterial communities within mammalian intestines, and by the construction of well-designed, controlled clinical trials of the effects of probiotics on inflammatory bowel disease (IBD). A number of review articles have been published during the last 2 years outlining the efficacy of probiotics, prebiotics, and synbiotics in the treatment of IBD.
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THE ROLE BACTERIA PLAY IN INFLAMMATORY BOWEL DISEASE
Several lines of experimental evidence implicate enteric flora in the pathogenesis of ulcerative colitis and Crohn's disease. First, the incidence of inflammation in the case of these disorders is greatest in the area with the highest concentrations of luminal bacteria. Second, the continuity of the fecal stream has been implicated in disease activity, and interruption of this stream is associated with disease improvement. Third, intestinal inflammation and mucosal ulceration can be induced by direct instillation of fecal contents from an inflamed gut into a non-inflamed gut of susceptible individuals. Fourth, there is growing evidence that suggests there is a genetically determined loss of immunologic tolerance to commensal bacteria in the case of patients who have IBD. Fifth, evidence pointing to the interaction of genes, immunity, and bacteria has emerged during the past half-decade, and the evidence is particularly noticeable in the case of a series of sporadic, engineered, and genetically determined animal models of IBD. In each of these models, enteric flora is required for the induction of the inflammatory process, regardless of the underlying genetic predisposition or immunologic effector mechanism defect. The discovery of the role enteric flora play as part of a common pathway to clinical IBD has led to renewed interest in, and increasing scientific assessment of, probiotic modification of the luminal bacterial environment for therapeutic reasons.
MECHANISMS OF ACTION OF PROBIOTIC BACTERIA IN INFLAMMATORY BOWEL DISEASE
It is clear that significant differences exist between probiotic bacterial species and strains. Previous research on probiotics has focused on their safety and ability to survive gastrointestinal transit relative to their use in the agriculture and food industry. However, during the past several years, significant advances have been made in understanding the mechanisms of action of individual strains as they relate to the pathophysiology of IBD. An understanding of these mechanisms of action will subsequently permit development of definitive criteria for selection of probiotic strains for specific clinical indications. It will also allow for the determination of optimal doses, timing of administration, and potential synergy between bacterial species.
Currently, beneficial effects of probiotic bacteria may be broadly classified into two main categories: (1) those effects arising due to activity in the large intestine related to colonization and inhibition of pathogen growth and (2) those effects related to enhancement of the host immune response and barrier function through interactions with epithelial and immune cells within both the small and large intestine. It is becoming clear that the functioning of the immune system at both a systemic and a mucosal level can be modulated by bacterial strains in the intestine. Immune cells are continually sampling and responding to intestinal microflora. 20 As well, different bacterial strains can signal through pattern-recognition receptors, thereby modulating various intracellular signaling pathways. 21, 22 Active constituents of bacteria that manipulate the mucosal immune system include enzymes 23 ; secreted protein factors 24 ; bacterial formulated peptides such as N-formylmethionine-leucine-phenylalanine (fMLP) and lipopolysaccharide (LPS) 22, 25 ; and peptidoglycan cell wall constituents including the muramyl dipeptide (MDP) MurNAc-L-Ala-DisoGln 26, 27 , gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP), 28 and bacterial deoxyribonucleic acid (DNA). [29] [30] [31] There are currently five, likely interrelated, probiotic mechanisms of action relative to therapy for IBD: (1) receptor competition, whereby probiotics compete with microbial pathogens for a limited number of receptors present on the surface epithelium; (2) immunomodulation and/or stimulation of immune function of gut-associated lymphoid and epithelial cells; (3) probiotic-induced suppression of pathogen growth through release of antimicrobial factors such as lactic and acetic acid, hydrogen peroxide, and bacteriocins; (4) probioticinduced enhancement of mucosal barrier function; and (5) induction of T-cell apoptosis in the lamina propria (Fig. 1) .
It remains to be established which potential mechanism(s) relate to the treatment of IBD and how the pathophysiology of clinical disease is altered through consumption of probiotics. However, it is clear from experimental models that probiotic strains differ greatly in their mechanisms of action, and that a single mechanism of action is unlikely to be responsible for their clinical effects (Table 1 ). In addition to specific interactions between probiotic bacteria and host immune cells, microbe-microbe interactions also exist. This could explain some of the varying results observed within the different clinical trials. One of the most widely accepted theories of IBD is that acute and chronic inflammation results from an interaction between susceptibility genes, luminal microflora, and a dysregulated immune system. It is likely that future research will FIGURE 1. Mechanisms of action of probiotics in therapy for inflammatory bowel disease. Five, likely interrelated, probiotic mechanisms of action relative to inflammatory bowel disease (IBD) are illustrated: (1) competitive exclusion, whereby probiotics compete with microbial pathogens for a limited number of receptors present on the surface epithelium; (2) immunomodulation and/or stimulation of an immune response; (3) probiotic-induced antimicrobial activity and suppression of pathogen growth through release of antimicrobial factors such as lactic and acetic acid, hydrogen peroxide, defensins, and bacteriocins; (4) probiotic-induced enhancement of barrier activity through mucin production and secretion; and (5) induction of T-cell apoptosis in the mucosal immune compartment. 79 Majamaa et al 80 Fang et al 81 Gill et al 82 Cano et al 83 Park et al 84 Shu et al 85 Braat et al 86 Roller Eijsink et al 105 Flynn et al 106 Park et al 107 result in the identification of clinical phenotypes in patients with IBD that respond to probiotic therapy and that specific strains will be characterized in order for a targeted therapeutic approach to occur.
POUCHITIS
Pouchitis is a nonspecific inflammation of the ileal reservoir and is a common complication following pouch surgery for ulcerative colitis. Its clinical frequency depends largely on the duration of the follow-up but is approximately 50% after 10 years. The cause of pouchitis remains unknown. However, recent studies have demonstrated reduced counts of lactobacilli and bifidobacteria within the pouch. This suggests that this syndrome may be the result of altered luminal microflora. 32 Though the majority of patients with pouchitis respond to treatment with antimicrobial agents, approximately 10% of patients experience recurrent or refractory disease. It was through well-designed clinical trials in these patients with pouchitis that the therapeutic potential of probiotics for IBD was initially demonstrated ( Table 2) .
Maintenance of Antibiotic-Induced Remission of Pouchitis
Gionchetti et al 33 conducted a randomized, doubleblind, placebo-controlled trial in 40 patients with acute active pouchitis. These patients were in clinical and endoscopic remission [with a score of zero in the clinical and endoscopic portion of the pouchitis disease activity index (PDAI)] after 1 month of antibiotic treatment with ciprofloxacin (1 g daily) plus rifaximin (2 g daily). They were then randomized to receive VSL#3 (two 3 g sachets once daily) [VSL Pharmaceuticals Inc., Fort Lauderdale, Florida, USA; 6 g per day containing 1.8 × 10
12 viable lyophilized colony forming units (cfu) per day of 4 strains of Lactobacillus (Lactobacillus casei, Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus delbrueckii subsp. Bulgaricus), 3 strains of Bifidobacterium (Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus] or placebo for 9 months. Of the 20 patients who received placebo, 100% had relapses within the 9-month period. In contrast, 17 of the 20 patients (85%) who received VSL#3 were still in remission with a PDAI of zero (eg, normal) after 9 months (p < 0.001). Furthermore, 100% of the patients receiving VSL#3 had relapses within 4 months after the VSL#3 treatment was stopped. These dramatic results provided the first conclusive evidence that, given the correct dose and combination, probiotics can play a major therapeutic role in the management of IBD. These authors also demonstrated that in patients treated with VSL#3, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus salivarius increased significantly compared with concentrations present before and after treatment. No changes were identified in concentrations of Bacteroides, coliforms, clostridia, enterococci, and total aerobes and anaerobes compared with basal levels. Once the VSL#3 was withdrawn, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus salivarius fell back to basal levels. Recently, the results with VSL#3 in the maintenance of antibiotic-induced remission have been replicated by a separate research group in a double-blind, placebo-controlled study. 34 This group similarly induced remission (PDAI of zero) in patients with active pouchitis with 4 weeks of combined metronidazole and ciprofloxacin. Patients were then randomized to receive either VSL#3 (1.8 × 10 12 cfu once daily) or placebo for 1 year. The only differences in this study, relative to that of the Gionchetti study outlined above, 33 were that the VSL#3 was given once daily rather than twice daily, and follow-up was 12 months rather than 9 months, respectively. Remission was maintained at 1 year in 17 patients (85%) on VSL#3 and in 1 patient (6%) on placebo. These results with the multispecies probiotic mixture (VSL#3) were virtually identical to those of the Gionchetti study. It also served to confirm the effectiveness of this specific probiotic regimen in the management of pouchitis. It is important to note that in both of these clinical trials, the quantity of VSL#3 was higher than that used in later studies and in current clinical practice.
Treatment of Acute Active Pouchitis
In contrast, Kuisma et al 35 did not demonstrate a therapeutic effect of probiotics in acute active pouchitis with a single-strain Lactobacillus rhamnosus GG formulation. In this randomized, double-blind, placebo-controlled trial, 44 subjects with acute inflamed pouches (PDAI of approximately 8; range 5 to 13) were randomized to receive Lactobacillus rhamnosus GG (4 × 10 10 cfu daily in two equal doses) or placebo for 3 months. No differences were found in the mean pretreatment or posttreatment PDAI scores between the two treatment groups. No significant changes were seen in the concentrations of aerobic or anerobic bacteria in the pouch. However, there was a trend toward higher fecal concentrations of total lactobacilli. Nevertheless, only 40% of study subjects were colonized with Lactobacillus GG. The cause of the negative therapeutic effects in this clinical trial with Lactobacillus rhamnosus GG remains to be determined. These results demonstrate the requirement for administration of multiple probiotic bacteria simultaneously (as are present in VSL#3) and/or a higher probiotic dose, or the need for pretreatment with antibiotics to induce remission prior to the probiotic therapy.
Laake et al 36 used an open, nonrandomized treatment with patients acting as their own controls. Ten subjects with acute active pouchitis were treated with 500 g of the dairy product Cultura (TINE Dairies BA, Oslo, Norway; 100 g contains 1 × 10 10 cfu of both Lactobacillus acidophilus and Bifidobacterium lactis, 3.2 g protein, 1.5 g fat, and 4.3 g carbohydrate). Cultura provided a daily intake of both lactobacilli and bifidobacteria (5 × 10 10 cfu) for 4 weeks. Seven of 10 patients had a reduced endoscopic score (using the endoscopic portion of the PDAI) after intervention and a 50% reduction in median values from 3.0 to 1.5 (p = 0.016). Interestingly, the histologic and laser Doppler flowmetry (LDF) scores, as a measure of inflammation, did not change with probiotic therapy. Thus, it is possible that the improvement in endoscopic score represents the bias of a single observer, nonblinded, endoscopic assessment in an open-label clinical trial. Microbiological assessment of the pouch confirmed that during the probiotic administration, 80% of patients had more lactobacilli. However, the differences did not reach statistical significance, and 1 week after the probiotic was stopped, the levels of lactobacilli returned to basal levels. Similar to the study by Kuisma et al, 35 treatment of acute active pouchitis with probiotics did not confer a positive therapeutic effect.
Postoperative Prevention of Pouchitis
To examine further the impressive clinical effect of VSL#3 in the management of pouchitis, the Italian group of Gionchetti et al 37 extended their observations to the use of VSL#3 in the postoperative prevention of pouchitis. They performed a randomized, double-blind, placebo-controlled trial where VSL#3 (9 × 10 11 bacteria per day) or placebo was administered for 12 successive months, beginning within 1 week after ileostomy closure and pouch formation. PDAI was assessed at 1, 3, 6, 9, and 12 months. Of the 20 patients randomized to receive VSL#3, 90% had normal pouch (with a PDAI of zero) after 1 year. In contrast, only 60% of patients randomized to receive placebo were in remission after 1 year (p < 0.05). Once again, in patients treated with VSL#3, there was no significant change in concentrations of Bacteroides, coliforms, clostridia, or enterococci in the pouches compared with the basal levels. In contrast, fecal concentrations of lactobacilli, bifidobacteria, and Streptococcus thermophilus were significantly increased compared with concentrations at baseline. In the placebo group, fecal concentrations of all species evaluated remained similar to that before starting treatment.
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CROHN'S DISEASE
Relative to the studies of probiotics in pouchitis, there are very few randomized, controlled clinical trials using probiotics in Crohn's disease. The results of the published clinical trials with probiotics in the treatment of Crohn's disease are shown in Table 3 , for treatment of acute active disease; Table  4 , for maintenance of medical-induced remission; and Table 5 , for maintenance of surgical-induced remission.
Treatment of Acute Active Disease
Gupta et al 38 conducted an open-label, pilot trial in children with mildly to moderately active disease [Pediatric Crohn's Disease Activity Index (PCDAI) > 10], in conjunction with concomitant therapy with prednisone and immunomodulatory agents. Patients received a 6-month, open-label evaluation of Lactobacillus GG (2 × 10 10 cfu per day). Four patients were enrolled in this pilot project. There was significant improvement in the PCDAI 1 week after beginning Lactobacillus GG. This improvement was sustained throughout the study, with the median PCDAI 73% lower than baseline. In three patients, it was possible to taper the dose of steroids while they were receiving Lactobacillus GG. Intestinal permeability, as determined by a double sugar permeability test, improved significantly with the Lactobacillus GG. Three patients had relapse of their Crohn's disease within 4-12 weeks of discontinuation of the Lactobacillus GG.
An open-label trial using the probiotic Lactobacillus salivarius UCC118 has also yielded encouraging results in treating acute active Crohn's disease. 39 Patients with active disease were given the opportunity to receive the probiotic Lactobacillus salivarius (1 × 10 10 cfu per day) instead of corticosteroids. Twenty-five patients enrolled, four dropped out with disease exacerbation, and two required corticosteroid therapy. Nineteen patients (76%) completed 3 months of treatment and were able to avoid other therapy. In addition, CDAI in these patients fell from a mean of 217 at entry to a mean of 150 at 3 months (p < 0.05). Controlled trials using this probiotic are currently underway. n/a n/a n/a <0.05 ns, not statistically significant; n/a, not applicable; RCT, randomized controlled trial.
Maintenance of Medical-Induced Remission
Inflamm Bowel Dis
Probiotics and the Management of IBD many) in a randomized, double-blind, placebo-controlled pilot study of corticosteroid-induced remission. Twenty-eight patients with active colonic Crohn's disease (CDAI > 150) were treated with prednisolone (60 mg per day) in a standard tapering regimen over 14 weeks. At the start of the prednisolone therapy, patients were randomized to receive either E. coli Nissle 1917 (5 × 10 9 cfu once daily) or placebo for 1 year. Using intent to treat analysis, the initial remission rate was 92% in the prednisolone and placebo group and 75% in the prednisolone and E. coli group (p = ns). Using per protocol analysis, the results were 92% and 86%, respectively. Once remission was achieved and the prednisilone had been tapered to zero, the percentage of patients that remained in remission at the end of 1 year was 70% in the E. coli Nissle 1917 treated group versus 30% in the placebo treated group (p = ns).
Guslandi et al 41 examined the role of Saccharomyces boulardii in the maintenance of remission in 32 patients with Crohn's disease. These patients had been in a medically induced remission for at least 3 months (CDAI < 150). At the time of entry into the study, the patients had been off all medications for at least 3 months. Patients were then randomized to receive mesalamine (Pentasa; Ferring Pharmaceuticals, Copenhagen, Denmark) (3 g daily in three divided doses) or mesalamine (Pentasa) (2 g daily in two divided doses) plus a preparation of Saccharomyces boulardii (1 g daily) for 6 months. Clinical remission at 6 months was observed in 10 of the 16 patients on mesalamine maintenance and in 15 out of sixteen patients receiving mesalamine Saccharomyces boulardii (p = 0.04). Despite this encouraging result, no further studies with Saccharomyces boulardii have been published. 
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Maintenance of Surgical-Induced Remission
Prantera et al 42 performed a randomized, double-blind, single-centered, placebo-controlled maintenance of surgicalinduced remission trial. Forty-five patients in clinical remission (CDAI < 150) were randomized to receive either Lactobacillus GG casei subspecies rhamnosus (1.2 × 10 10 cfu daily) or placebo within 10 days following surgical resection of their Crohn's disease. After 52 weeks of treatment, 15 patients (83%) treated with Lactobacillus GG and 17 patients (89%) treated with placebo remained in clinical remission (p = 0.948). In contrast, endoscopic remission was identified in 6 patients (40%) in the Lactobacillus GG group, compared with 11 patients (65%) in the placebo group (p = 0.243). Considering the success of Lactobacillus GG in the prevention of antibiotic-, Clostridium difficile-, and childhood-diarrhea, the reason for these marked negative results in the maintenance of surgical-induced remission in Crohn's disease remains speculative. It may be that, similar to the results seen with pouchitis, treatment with certain single species of probiotics is less effective than combination agents. Whether this represents individual species selection or quantity of bacteria delivered and/or colonized remains to be determined.
Campieri et al 43 reported, in abstract form, that a combination of antibiotic and the probiotic mixture (VSL#3) treatment was efficacious in prevention of the postoperative recurrence of Crohn's disease when compared with mesalamine. Forty patients were randomized to receive either rifaximin (1.8 g per day) for 3 months followed by VSL#3 (6 × 10 11 cfu per day) for 9 months, or mesalamine (4 g per day) for 12 months. After 1 year, the antibiotic/VSL#3 group had an endoscopic remission rate of 80% compared with 60% in the mesalamine group (p < 0.05). Interestingly, these endoscopic remission rates at 1 year with an antibiotic followed by VSL#3 are similar to those that have previously been described with metronidazole alone. 44 
ULCERATIVE COLITIS
The results of the published clinical trials with probiotics in the treatment of ulcerative colitis are shown in Table 6 for treatment of acute active disease and in Table 7 for maintenance of remission.
Treatment of Acute Active Disease
In 1999, Rembacken et al 45 conducted a single-center, randomized, double-dummy study examining 116 patients cfu per day in two divided doses). At entry into the study, all patients were given an initial 1-week course of oral gentamicin (80 mg three times daily) to suppress their native E. coli flora. Along with the study, probiotic or mesalamine patients were also permitted to receive treatment with tapering prednisolone for moderate and severe disease and rectal hydrocortisone enemas for proctitis for 3 months to induce remission. After entering into remission, patients were maintained on either mesalamine or E. coli for up to 12 months. Forty-four patients (75%) in the mesalamine group and 39 patients (68%) in the E. coli group attained remission. The median time to remission was similar in both groups. At the end of 12 months, 25% of patients in the mesalamine group and 26% of patients in the E. coli group maintained remission. The median duration of remission was similar in both groups. The authors suggest that treatment with this nonpathogenic E. coli has an equivalent effect to mesalamine in maintaining remission. Nevertheless, the study was not powered for equivalence, and the remission rates at 1 year were close to historical placebo rates.
Recently, Fedorak et al 46 evaluated the efficacy of VSL#3 in an open-label, two-center trial with 30 patients with active mild to moderate ulcerative colitis. These patients had failed mesalamine therapy and were treated with VSL#3 (1.2 × 10 12 cfu daily in two divided doses) for 6 weeks. Remission, as determined by an ulcerative colitis clinical score of <3, was achieved in 63% of VSL#3-treated patients. Response, as determined as an ulcerative colitis clinical score of a decrease of Ն3 and a final value of Ն3, was achieved in 23% of VSL#3-treated patients. No response was found in 13% of the treated patients. This represents a significant improvement in a difficult to treat population. A randomized, controlled trial is underway to confirm these results. longum, B. breve, and B. infantis) , and 1 strain of Streptococcus salivarius subsp thermophilus. Yakult (Yakult Honsha Co., Ltd., Tokyo, Japan). ns, not statistically significant; n/a, not applicable; RCT, randomized controlled trial.
Guslandi et al 47 studied 25 patients with a clinical flare of their ulcerative colitis of a mild to moderate degree, according to Truelove and Witts' criteria. The patients were on maintenance mesalamine (3 g per day) for at least 3 months. Only patients who had a history of poorly tolerating corticosteroids were permitted to enter the study. In this open-label trial, patients received Saccharomyces boulardii (750 mg per day in three divided doses) for 4 weeks while their ongoing mesalamine was continued. Clinical disease activity score, before and after probiotic therapy, was determined by the Rachmilewitz ulcerative colitis activity index; it is calculated on the basis of stool frequency, blood in the stool, general condition, fever, abdominal pain, erythrocyte sedimentation rate, and hemoglobin values. A significant reduction in the ulcerative colitis activity index score was observed at the end of treatment (p < 0.05), and remission (a disease activity score Յ 5) was achieved in 17 of 25 patients (68%). 47 Interestingly, the remission rate in this pilot study is remarkably similar to the remission rates described above for E. coli Nissle 1917 and VSL#3.
A recent intriguing study by Borody et al, 48 slightly outside of the true probiotic realm, used fecal bacteriotherapy (fecal enemas) in six patients. These patients had failed maximum standard therapy for ulcerative colitis, including multiple courses of corticosteroids and immunosuppressive therapy. Fecal enemas were prepared fresh (in normal saline) from healthy adult donors, nominated by the patients and administered once daily for 5 consecutive days as enemas (retained for 6-8 hours). In addition to the fecal enemas, patients were prescribed a high-fiber diet in attempt to stimulate proliferation of infused bacteria. In a series of case reports, the authors document that these six patients were able to withdraw all concurrent ulcerative colitis medication approximately 4-6 weeks following completion of the fecal enema therapy. In 1-13 years of follow-up, there has been no clinical, colonoscopic, or histologic evidence of ulcerative colitis recurrence in any patient, despite the fact that no maintenance therapy has been used. 48 Clearly, these results are dramatic and worthy of further investigation both from a pathogenesis as well as a therapeutic standpoint.
Maintenance of Remission
In 1997, Kruis et al 49 examined 120 patients with inactive ulcerative colitis. These patients were included in a double-blind, double-dummy study comparing mesalamine (Salofalk; Axcan Pharma Inc., Houdan, France) (1.5 g per day in three divided doses) to an oral preparation of E. coli Nissle 1917 (5 × 10 10 cfu per day as a single dose) for 3 months. Clinical remission was defined by the Rackmilewitz disease activity index score. Seventeen patients could not be included in the data analysis, and thus intent-to-treat analysis was based on results of 103 patients. At the end of 3 months, remission rates were 89% in the mesalamine group and 84% in E. coli Nissle 1917 group (p = 0.12). The authors concluded that E. coli Nissle 1917 was equivalent to mesalamine in maintenance of remission. Nevertheless, it is possible that the dose of mesalamine used was near placebo and the study was not adequately powered for equivalence.
In 2001, Kruis et al 50 published, in abstract form, a larger and longer duration follow-up clinical trail than their initial maintenance of remission study. There were 327 patients with ulcerative colitis in medically induced remission included in this double-blind, randomized, controlled study comparing mesalamine (Salofalk) (1.5 g per day in three divided doses) to an oral preparation of E. coli Nissle 1917 (5 × 10 10 cfu per day as a single dose) for 12 months. Clinical remission was defined using the Rackmilewitz disease activity index score. At the end of 12 months, remission rates were 64% in the mesalamine group and 55% in E. coli Nissle 1917 group (p = ns). Once again, the authors concluded that E. coli Nissle 1917 was equivalent to mesalamine in the maintenance of remission of ulcerative colitis.
Venturi et al 51 (1 × 10 12 cfu daily in two divided doses) for 12 months. Patients were assessed clinically every 2 months and assessed endoscopically at 6 and 12 months. In this study, clinical remission was defined as absence of visible blood in the stools and no more than two bowel movements per day. Endoscopic remission was defined as a score of zero in accordance with the Baron's ulcerative colitis index. Fifteen of 20 treated patients (75%) remained in remission at the end or 12 months of study. 51 Once again, significant concentrations of the probiotics present in the VSL#3 were identified in fecal cultures. There were no significant changes in fecal concentration of Bacteroides, clostridia, coliforms, or total aerobic and anaerobic bacteria.
Finally, Ishikawa et al 52 conducted a randomized, controlled trial study in 21 patients to examine the effect of bifidobacteria-fermented milk in patients with ulcerative colitis in remission. Patients received fermented milk (Yakult ® , Yakult Honsha Co., Ltd, Tokyo, Japan) that contained live bifidobacteria (Bifidobacterium breve and Bifidobacterium bifidum) and Lactobacillus acidophilus (1 × 10 10 cfu per 100 mL once daily) for 12 months. Remission was defined clinically as any global increase in symptoms. Compliance at the 95% level was limited to 7 out of 11 patients consuming the fermented milk product. At the end of 12 months, clinical remission was seen in 8 out of 11 subjects (73%) taking the fermented milk and in 1 out of 10 subjects (10%) taking placebo. 52 Interestingly, despite this significant difference in clinical remission rates, there were no significant differences in the colonoscopic findings at 1 year. This raises the question as to the validity of the clinical assessment tool used in this trial. Furthermore, there were no differences between the two groups in total fecal bacterial counts or in bifidobacteria counts. However, the authors were able to recover (from the feces) the bifidobacteria strains present in the fermented milk. A larger, multicenter study with this probiotic product is currently underway.
GENETICALLY ENGINEERED PROBIOTICS
Recently, murine interleukin (IL)-10 synthesis and secretion by genetically modified Lactococcus lactis was shown to be an efficient way to deliver high concentrations of this anti-inflammatory cytokine. 53 When these Lactococcus lactis were administered to murine experimental models of IBD, IL-10 was delivered to the mucosal surface at a concentration that reduced or prevented the onset of enterocolitis. 54 These studies introduced new and exciting proof of the ability to merge cytokine therapy for IBD with genetic engineering of probiotics. The safety issues related to the genetic modification of this probiotic have been addressed by replacing the thymidylate synthase gene in the Lactococcus lactis with a synthetic human IL-10 gene. This thymidylate synthase negative, human IL-10 positive Lactococcus lactis strain produces human IL-10. However, when it is deprived of thymidine or thymine, the strain is not viable and is eliminated by the mouse body. 55 Theoretically, this built-in biologic containment system should prevent accumulation of the genetically modified probiotic in the mammalian environment. Currently, a pilot trial, involving humans with Crohn's disease, is underway to examine the therapeutic safety and efficacy of this human IL-10 secreting Lactococcus lactis. As the understanding of human IBD develops, the use of bacteria as "Trojan horses" to deliver a host of therapeutic agents should provide exciting possibilities.
SAFETY
The results of a recent international workshop on the safety of lactobacilli and bifidobacteria have been published. 56 There are certainly many common sources of exposure to probiotics, including packaged therapeutic products, fermented foodstuffs (eg, yogurt, cheese, and fermented vegetables), and human microflora in the oral cavity, intestine, and vagina. This is why many of the commercial probiotic products have been officially designated as "generally regarded as safe." There seems to be no evidence that deliberately ingested lactobacilli or bifidobacteria pose any risk of infection greater than that associated with commensal strains.
Cases of infection due to probiotics are extremely rare; they are estimated to represent between 0.05% and 0.4% of cases of infective endocarditis or bacteremia. 57, 58 During the last 30 years, 180 cases of lactobacillemia have been reported, and 69 cases of infective endocarditis have been attributed to lactobacilli. 56 In an important prospective study from Finland, the marked increase seen in the consumption of probiotics by consumers has not led to an increased rate of opportunistic infection by these same probiotics. 59, 60 This study provides reassurance that the introduction of probiotics as therapeutic agents has not, and should not, result in increased rates of human infections. Indeed, most of the rare cases of such infections occur in the case of immunocompromised patients or those with serious underlying disease states. [61] [62] [63] [64] [65] [66] [67] [68] [69] Obviously, the provision of probiotics to this group of patients should be approached with caution. Though several attempts have been made to evaluate the factors that might predispose such severely ill patients to infection by probiotics, 61 ,63 statistical analysis is lacking, and the number of cases is too small to permit the drawing of any statistically valid conclusions. Studies done on children have shown that probiotic compounds containing lactobacilli and bifidobacteria are well tolerated by, and safe for, this age group. [70] [71] [72] Despite these reassuringly low infection rates for healthy humans, it will still be important to monitor probiotic treatment safety through rigorous identification of infecting organisms. These identifications should be verified by molecular studies, as physiological characterization alone is insufficient for reliable classification. For new probiotic products where the organism is not present in the traditional diet, a more aggressive safety analysis (one similar to that used for pharmacologic compounds) must be followed. Finally, antibiotic resistance to probiotic bacteria is not a hazard, unless it renders the probiotic untreatable, as in the rare case of infection. In this regard, all strains of such probiotics should be susceptible to a number of major antibiotics, certainly to more than two.
SUMMARY
The human gut flora is part of an exceedingly complex ecosystem. It is clear that individuals with a genetic predisposition to the development of IBD do so in response to the presence of luminal bacteria. Furthermore, these luminal bacteria appear to be central not only to the initiation, but also to the perpetuation of intestinal inflammation. Probiotic bacteria appear to modulate a number of the proinflammatory pathways. Understanding of the mechanisms of action of these probiotic bacteria, especially in the case of IBD, will permit the development of definitive criteria for the selection of probiotic strains useful for clinical application. It will also allow for the determination of optimal doses, timing of administration, and synergistic combinations of bacterial species. Currently, beneficial effects exerted by probiotic bacteria may be broadly classified as (1) those effects that arise due to activity in the large intestine and are related to either colonization or inhibition of pathogen growth, and (2) those effects that arise in both the small and large intestine and are related to enhancement of the host immune response and barrier function through interactions with epithelial and immune cells. It is becoming increasingly clear that the functioning of the immune system, at both a systemic and a mucosal level, can be modulated by bac-terial strains in the intestine. The advent of molecular techniques that allow us to quantify, identify, and determine the genomics and proteomics of luminal bacteria and probiotics will significantly advance this area of research. We will need to determine if the use of a single probiotic, or the use of combinations of probiotics, present the best therapeutic approach. We also need to better investigate dosing and colonization issues. Appropriately designed, randomized, controlled clinical trials have clearly identified a therapeutic role for some probiotics in the case of pouchitis. Nevertheless, the plethora of pilot, open-label, and poorly designed clinical trails, as seen in the cases of Crohn's disease and ulcerative colitis, can be read as tending to overstate the promise of probiotics. Rigorously designed, controlled clinical trials must be constructed to investigate issues related to efficacy, dose, duration of use, single or multi-strain formulation, and the concomitant use of prebiotics, synbiotics, and antibiotics.
